FibroBiologics reported cash from operations of -$3.29M and free cash flow of -$3.29M for the quarter ended Jun 2026, up 17.4% year over year. This cash flow statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Net Income | -2.40M | -2.10M | -2.05M | -2.48M | -3.42M | -3.16M | -3.28M | -3.65M | -4.43M | -4.44M | -4.96M | -2.77M | -5.05M | -4.03M | |
| Share-based Compensation | 0.10M | 0.45M | 0.45M | 0.44M | 0.43M | 4.01M | 4.01M | 4.03M | 0.54M | 5.37M | 5.93M | 5.72M | 0.70M | 4.16M | 3.87M |
| Gains from Investment Securities | 3.10M | -5.53M | -1.93M | -1.04M | |||||||||||
| Cash from Operations | -2.04M | -1.62M | -1.14M | -1.60M | -4.28M | -1.95M | -2.61M | -3.07M | -5.28M | -3.98M | -3.97M | -3.16M | -4.36M | -3.29M | |
| Depreciation, Depletion & Amortization | |||||||||||||||
| Amortizatization of Intangibles | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.11M | 0.11M | 0.52M | 0.17M | 0.10M | |||
| Amortization of Deferred Charges | 1.94M | ||||||||||||||
| Change in Working Capital | |||||||||||||||
| Change in Receivables | 0.28M | ||||||||||||||
| Change in Accured Expenses | 0.20M | -0.02M | 0.22M | 0.28M | -0.63M | 0.39M | -0.03M | 1.52M | -1.03M | 0.38M | -0.73M | -0.12M | -0.10M | 0.97M | |
| Other Working Capital Changes | -0.09M | -0.09M | -0.09M | -0.05M | -0.10M | -0.10M | -0.10M | -0.06M | -0.11M | -0.14M | -0.17M | -0.13M | -0.18M | -0.07M | |
| Investing Activities | |||||||||||||||
| Capital Expenditures | 0.06M | 0.02M | 0.41M | 0.00M | 0.01M | 0.07M | 0.01M | 0.10M | 0.04M | 0.21M | 0.01M | ||||
| Cash from Investing Activities | -0.06M | -0.02M | -0.41M | -0.00M | -0.01M | -0.07M | -0.01M | -0.10M | -0.04M | -0.21M | -0.01M | ||||
| Financing Activities | |||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||
| Long-Term Debt Issuances | 4.38M | 0.33M | |||||||||||||
| Short-Term Debt issuances | 0.57M | 4.38M | -4.38M | ||||||||||||
| Change in Capital Stock | |||||||||||||||
| Net Shares Issued and Repurchased | 3.69M | 0.22M | 0.01M | 0.76M | 0.83M | 1.39M | |||||||||
| Net Equity Issued and Repurchased | 2.82M | 4.64M | 0.04M | 0.71M | 2.86M | ||||||||||
| Misc. | |||||||||||||||
| Cash from Financing Activities | 14.57M | -1.71M | 0.94M | 3.28M | -0.17M | 4.47M | 9.33M | 4.38M | 3.19M | 0.95M | 5.32M | ||||
| Change in Cash | 12.47M | -3.36M | -0.61M | -1.60M | -1.00M | -2.19M | 1.85M | 6.16M | -5.32M | 0.18M | -3.98M | 0.03M | -3.41M | 2.03M | |
| Free Cash Flow | -2.09M | -1.65M | -1.55M | -1.60M | -4.28M | -2.01M | -2.62M | -3.17M | -5.32M | -4.20M | -3.98M | -3.16M | -4.36M | -3.29M | |
| Net Cash Flow | 12.47M | -3.36M | -0.61M | -1.60M | -1.00M | -2.19M | 1.85M | 6.16M | -5.32M | 0.18M | -3.98M | 0.03M | -3.41M | 2.03M |